Revvity reported a strong finish to 2025, with Q4 revenue of $772 million (+4% organic) and full-year revenue of $2.86 billion (+3% organic), exceeding initial guidance despite significant headwinds including NIH funding shifts, tariffs, and China DRG pressures. Adjusted EPS for the quarter was $1.70, beating the high end of guidance, while full-year adjusted EPS reached $5.06, representing 3% year-over-year growth. The company demonstrated robust capital stewardship by repurchasing over $800 million in shares during 2025, reducing the share count by 8.5 million shares. Looking ahead to 2026, management issued conservative guidance for 2-3% organic growth and adjusted EPS of $5.35-$5.45, driven by the recent ACD Labs acquisition, new AI product launches (Signals Synthetica), and ongoing cost efficiency initiatives expected to expand operating margins to 28%.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $772 million | +4% Organic |
| FY 2025 Revenue | $2.86 billion | +3% Organic |
| Q4 Adjusted EPS | $1.70 | Beat by $0.06 vs high end |
| FY 2025 Adjusted EPS | $5.06 | +3% YoY |
| Q4 Adjusted Operating Margin | 29.7% | -60 bps YoY |
| FY 2025 Adjusted Operating Margin | 27.1% | -120 bps YoY |
| FY 2025 Free Cash Flow | $515 million | 87% Conversion |
| Share Repurchases (2025) | $800 million | 8.5M shares retired |
Revvity is making a significant strategic pivot into AI-driven drug discovery with the launch of 'Signals Synthetica,' an AI models-as-a-service platform. This platform integrates directly into the existing Signals software suite, which is already embedded in nearly all major pharma companies. The collaboration with Eli Lilly's TUNE lab initiative, where Lilly shares proprietary AI models in exchange for data, provides a strong validation of the platform's utility and creates a unique 'lab-in-the-loop' workflow that could drive high switching costs and recurring revenue.
Capital allocation remains a primary strategic pillar, with management returning significant cash to shareholders while simultaneously investing in transformative acquisitions. The company repurchased over $800 million of stock in 2025 (12% of share count since 2023) and closed the ACD Labs acquisition in January 2026. This 'opportunistic and disciplined' approach signals management's belief that the stock is undervalued and highlights their ability to self-fund growth through strong free cash flow conversion (87% in 2025).
The Diagnostics segment demonstrated surprising resilience and outperformance, particularly in Reproductive Health and Newborn Screening, which grew mid-single and high-single digits respectively. This strength allowed the segment to achieve 7% organic growth in Q4. Management highlighted that this outperformance against underlying birth rates is due to 'fantastic operational and commercial execution,' suggesting market share gains and operational leverage that can persist even if macro conditions remain challenging.
Management is executing a multi-faceted cost efficiency program expected to be fully completed by the end of Q2 2026. These initiatives, including footprint consolidations and supply chain synergies, are forecast to drive adjusted operating margins up to 28% in 2026 from 27.1% in 2025. This focus on operational excellence, combined with the pivot to higher-margin software revenue (ACD acquisition), positions the company for significant margin expansion as revenue growth accelerates.
Management issued conservative 2026 guidance (2-3% organic growth) that implies a deceleration from the Q4 print (4% organic growth), despite citing 'encouraging signs' like stronger biopharma funding and M&A. This conservatism creates a risk that the guide is overly cautious, but more critically, it highlights management's lack of visibility or trust in the sustainability of the recent recovery, particularly in Academic and Government end markets which remain under pressure.
The Immunodiagnostics business in China continues to face structural headwinds from DRG-related volume pressures, with management now taking a 'more prudent assumption' that the business will be 'down slightly' in the second half of 2026 rather than returning to growth. While this is a small portion of total revenue (<5%), the persistent weakness and the need to anniversary these headwinds indicate a prolonged slowdown in this key market.
Q1 2026 profitability faces a notable structural headwind from the 'extra week' in the quarter (14 weeks vs 13), which acts as a margin drag due to additional labor costs. Management guided Q1 operating margins to be approximately 23%, significantly lower than the full-year target of 28%. This seasonal and calendar distortion could cause a negative stock reaction if investors focus on the margin compression rather than the one-time nature of the cost.
The Life Sciences Instruments business, while showing sequential improvement in Q4 (roughly flat YoY), is still projected to be 'flattish' for the full year 2026. This suggests that the capital expenditure environment for pharma and biotech customers remains fragile, and a recovery in instrument sales—which are typically high-margin and cyclical—may take longer to materialize than anticipated by bullish investors.
Overall: Management exhibited a tone of resilient confidence and disciplined stewardship. Prahlad Singh emphasized the company's ability to execute amidst 'dynamic' challenges, while CFO Maxwell Krakowiak balanced pride in the year's operational achievements with a prudent, conservative outlook for 2026. The tone shifted from highlighting the strong Q4 beat and aggressive share buybacks in prepared remarks to a more defensive, cautious posture during Q&A regarding the conservative guidance.
Confidence: HIGH - Management demonstrated high confidence through aggressive capital allocation (repurchasing 12% of shares since 2023) and bold strategic moves like the ACD acquisition and AI platform launch. However, they displayed medium confidence regarding the immediate macro recovery, explicitly choosing to 'remain cognizant' and 'prudent' in their 2026 assumptions despite positive market signals.
2% to 3%
$2.96 billion to $2.99 billion
$5.35 to $5.45
28%
2% to 3%
~23%
Hedging & Uncertainty: Management frequently utilized hedging language to temper expectations regarding the 2026 outlook. Terms like 'prudent assumption,' 'fluid end market,' and 'modest improvement' were used to frame the conservative guidance. Max Krakowiak explicitly stated they are 'not really modeling any improvement' in preclinical markets and are taking a 'conservative and prudent approach' on China. This heavy use of qualifiers suggests management is prioritizing under-promising to ensure they can over-deliver, reflecting a lack of confidence in the macro environment despite the company-specific execution.
Appropriately prudent with our initial outlook for this year given continued market uncertainties - Maxwell Krakowiak, SVP and CFO
We are not really embedding any material benefit from those software launches in 2026. - Maxwell Krakowiak, SVP and CFO
I would say we are no longer forecasting a return to low single-digit growth in the second half of the year. - Maxwell Krakowiak, SVP and CFO
We've got to see this for a longer period of time before we... make a call and it true durable uptake. - Prahlad Singh, President and CEO
We are taking a little bit more, I say, of a conservative and prudent approach on some of the expectations for our China IDX business. - Maxwell Krakowiak, SVP and CFO
Analyst Sentiment: Analysts were generally inquisitive but skeptical of the conservatism embedded in the 2-3% organic growth guidance, specifically questioning why the guidance wasn't raised given recent positive signals in biotech funding and M&A activity. There was a focus on understanding the 'prudence' versus fundamental weakness in China and the instruments business.
Management Responses: Management remained disciplined in their responses, consistently reiterating that the guidance assumes a continuation of recent trends rather than a full recovery. They used phrases like 'prudent assumption' and 'not really modeling any improvement' to defend the low guide, while explicitly leaving the door open for upside if conditions persist.
Discussion on the conservatism of the 2-3% organic guide and potential for upside from biotech funding and M&A.
Deep dive into the China Immunodiagnostics (IDX) weakness and the rationale for the 'down slightly' outlook for H2 2026.
Inquiries regarding the uptake trajectory and revenue contribution of new software launches (Biodesix, Synthetica) and the ACD acquisition.
Questions on the durability of the Q4 Diagnostics strength (Newborn Screening) and the specific headwinds facing the Instruments business in 2026.
Revvity presents a compelling opportunity driven by a unique combination of aggressive shareholder returns and a strategic pivot into high-growth AI/Software markets. The company's 12% reduction in share count since 2023 signals strong confidence in intrinsic value, while the launch of Signals Synthetica and the Lilly partnership position them as a leader in the AI-enabled drug discovery workflow. Although the 2-3% organic growth guide for 2026 appears conservative, it likely sets the stage for significant beats and raises as the biotech funding environment recovers and cost synergies (targeting 28% margins) flow through the P&L. The resilience of the Diagnostics segment provides a stable floor, while the Software/AI segment offers a multi-year growth engine.
Management noted 'stronger biopharma funding' and 'greater clarity on future NIH funding,' suggesting the capital markets freeze for early-stage biotech is thawing, which drives demand for preclinical research tools.
Ongoing DRG (Diagnosis Related Groups) volume pressures in China continue to suppress demand for Immunodiagnostics, with management now expecting the business to be down slightly in H2 2026 rather than recovering.
Increased M&A activity in the biotech sector was cited as a positive indicator, as consolidation typically leads to increased R&D spending and integration of discovery platforms, benefiting Revvity's tools and software.
Sales to academic and government customers declined in the low single digits, impacted by the 'extended US government shutdown' and funding uncertainty, though management expects this to be less challenged in 2026 than 2025.